Exousia Pro

MAJI · OTC

$0.0038+$0.0004 (+11.76%)TodayMarket closed · Oct 20, 3:44 PM ET

Prev close $0.0034

About MAJI

Marijuana, Inc. operates as a shell company seeking to merge with another entity with experienced management and opportunities for growth. The company is headquartered in Saint Petersburg, Florida. The company went IPO on 2010-12-28. The firm's mammalian exosomal technology platform has shown the capability to increase the efficacy of Merck's drug Temozolomide (TMZ) in the treatment of glioblastoma (GBM). Its patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The firm's proprietary loading technology can infuse a range of molecules from drugs to deoxyribonucleic acid (DNA).

Employees: 0
Headquarters: Saint Petersburg, Florida
Listed: Dec 28, 2010
Sector: Health Care
Industry: Biotechnology
Website: exousiapro.com

Leadership

Exousia Pro executives
Name	Title	Since	Age
Justin Costello	—	2019	38
David Cutler	—	2012	59
Donald Ross	—	—	64

Similar companies

Companies in the same industry as Exousia Pro

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.